“…Studies have consistently shown the use of DAAs against HCV to be cost-effective [10][11][12][13][14][15][16][17][18]. These studies differ in the country of origin, base populations, comparative treatment groups, and a variety of assumptions such as reinfection rates (See Table 1).…”